help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on December 12, 2006
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-2189
A more recent version of this article appeared on March 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
92/3/1164    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baumgartner-Parzer, S M
Right arrow Articles by Vierhapper, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baumgartner-Parzer, S M
Right arrow Articles by Vierhapper, H

Submitted on October 6, 2006
Accepted on December 1, 2006

Predisposition for de novo gene aberrations in the offspring of mothers with a duplicated CYP21A2 gene

S M Baumgartner-Parzer*, G Fischer, and H Vierhapper

Dept. of Internal Medicine III, Division of Clinical Endocrinology and Metabolism, Dept. of Blood Group Serology, Medical University of Vienna, Vienna, Austria

* To whom correspondence should be addressed. E-mail: sabina.baumgartner-parzer{at}meduniwien.ac.at.

Context: Although CYP21A2 de novo mutations are assumed to account for 1-2% of CAH- alleles, and CYP21-genotyping has been done worldwide, there are only a few well documented cases of CYP21A2 de novo mutations. The majority of these are deletions due to unequal crossingovers owing to misalignment of homologous chromosomes during meiosis. Whereas so far only heterozygous deletions of the CYP21A1P pseudogene were seen as premutations for de novo aberrations, the present report addresses such a predisposing role for parental duplicated CYP21A2 genes.

Subjects and Methods: As part of routine diagnostic procedures CYP21A-genotyping has been performed in two unrelated female CAH index patients and in their clinically asymptomatic parents and siblings.

Results: Both patients have inherited the paternal Intron2splice (IVS2) mutation and have harboured a de novo gene aberration (large deletion and I271N/Exon 4) on their maternal haplotype. Surprisingly, both mothers were carriers of rare duplicated CYP21A2 haplotypes carrying CAH-alleles, which were not detected in the daughters. Among 133 CAH-alleles, that were detected in patients and that could be traced to the respective family members by genotyping, these two de novo aberrations (representing 1.5% of 133 traced CAH-alleles) were the only ones identified.

Conclusion: Since both de novo CYP21A2 gene aberrations so far identified in our laboratory, occurred in the gametes of mothers carrying rare duplicated CYP21A2 haplotypes, we hypothesize that duplicated CYP21A2 genes could predispose for de novo mutations in the offspring, which is of relevance for prenatal CYP21-genotyping and genetic counseling.


Key words: Congenital adrenal hyperplasia • 21-hydroxylase deficiency • duplicated CYP21A2 gene • de novo gene aberrations • pre-mutation







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society